about
Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapyPostoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007Collecting direct non-health care and time cost data: application to screening and diagnosis of cervical cancer.A randomized controlled trial to assess the efficacy of an interactive mobile messaging intervention for underserved smokers: Project ACTION.Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors.Impact of ileostomy-related complications on the multidisciplinary treatment of rectal cancer.Plastic Surgeon Expertise in Predicting Breast Reconstruction Outcomes for Patient Decision Analysis.A comparison of C/B ratios from studies using receiver operating characteristic curve analysis.Screening for squamous intraepithelial lesions with fluorescence spectroscopy.Assessing Women's Preferences and Preference Modeling for Breast Reconstruction Decision-Making.Cost of contralateral prophylactic mastectomyTreatment decisions for localized prostate cancer: a concept mapping approachRisk-adjusted pathologic margin positivity rate as a quality indicator in rectal cancer surgeryBayesian meta-analysis of Papanicolaou smear accuracy.Accuracy of optical spectroscopy for the detection of cervical intraepithelial neoplasia: Testing a device as an adjunct to colposcopy2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer.Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices.Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasiaPreferences of husbands and wives for outcomes of prostate cancer screening and treatment.Aspirin for primary prevention of cardiovascular events.Cost-effectiveness analysis of smoking-cessation counseling training for physicians and pharmacistsOptical technologies and molecular imaging for cervical neoplasia: a program project update.Accuracy of optical spectroscopy for the detection of cervical intraepithelial neoplasia without colposcopic tissue information; a step toward automation for low resource settings.Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status.Disparities in cervical cancer survival among Asian-American womenQuality-adjusted survival following treatment of malignant pleural effusions with indwelling pleural catheters.Optimizing clinical and economic outcomes of surgical therapy for patients with colorectal cancer and synchronous liver metastases.The clinical effectiveness of optical spectroscopy for the in vivo diagnosis of cervical intraepithelial neoplasia: where are we?Comparing performance of the CADstream and the DynaCAD breast MRI CAD systems : CADstream vs. DynaCAD in breast MRI.The performance of human papillomavirus high-risk DNA testing in the screening and diagnostic settingsPsychological benefits of prostate cancer screening: the role of reassuranceUse of forecasted assessment of quality of life to validate time-trade-off utilities and a prostate cancer screening decision-analytic model.Engaging physicians and pharmacists in providing smoking cessation counseling.'It's not like you just had a heart attack': decision-making about active surveillance by men with localized prostate cancer.Recommendations for enhancing clinical trials education: a review of the literature.A primer on cost-effectiveness analyses for vascular surgeons.Developing a system to track meaningful outcome measures in head and neck cancer treatment.Comparative effectiveness research in pediatric radiology.Impact of generic drug entry on cost-effectiveness analysis.
P50
Q28208442-E5F0789C-6E0C-4B42-AB4B-7B4D2A6EB20DQ30744596-A5BBEFD4-CC60-40EB-80B4-A1D98BEC4B6DQ31043345-9791D628-2215-4145-9B63-ACF3292CE19FQ31087329-F825CCCD-36C6-4921-8B6D-177F1E6983F3Q33346849-5FD2093D-CC05-4014-BABC-E5C9E0F33D56Q33632227-1F0CDA43-B6E9-4A5D-A1EB-1B8EB6D6D781Q33708728-71CBE4C3-0AAD-4C8F-9934-0BE914E342D7Q33755734-967895B9-C83C-4891-ACB2-DB6F86AD057AQ33765162-17036ECB-3870-41D7-92E0-42F7BCD1A380Q33998713-0132EE5B-902A-4BE8-A511-3A9124B703DEQ34017128-99CFFEB6-7BA3-430C-8722-2996CF802991Q34028603-AE8C638C-C190-421E-916B-4176D7ADB926Q34172017-E45BD541-94F4-46B7-B70B-5C2BA55E3CB9Q34244723-72BDDFE4-F2EF-44EC-81C6-7FC1258492E4Q34462106-2C13321E-E022-4C75-87B4-19E599797CB6Q34523108-E9720827-4892-4C21-8E0F-5B62C4834873Q34552583-1762041A-FA8D-4E22-860C-9BDAF8CDE656Q34571314-8E97189C-030C-4512-B242-E6E0E304B964Q34625933-0F8C4D87-5197-470E-B36F-9B92F63C00E1Q34732064-58C8D5ED-7A6F-463E-91E7-3665134DBF91Q34752312-D5BFB887-E581-4FD4-8232-9492F3FAB159Q35217687-2EED3B89-F1FB-4929-ABB0-9E9E3C54EA42Q35788539-B4FAFF38-D6E6-48C7-A0AA-C9F7E9AFAA28Q36051726-CA9B512E-0F81-4FC1-9122-03FCEE9C8E5CQ36339415-F5B96D73-2B1B-4AEE-85B9-366746C1F3C5Q36395696-A47AB011-DDCC-44E9-B44D-C8E15255CCF1Q36411373-753F7EBD-14BA-4AA5-82DF-9EC6D01600B8Q36944204-BC52DAE3-6605-4E53-81CC-A344CF57836FQ36956995-6702267E-7CD2-4218-9690-1D4508DED0B1Q37196256-3B157C50-FE8B-42F8-94AF-3D6A3F3A057EQ37250812-36B38C41-C040-4EB4-AA8C-A57CE5921CA1Q37331455-8988811A-799A-483E-88AD-7C8D73B327B3Q37333404-D417464E-D137-46C0-837D-91D325BD25ADQ37385048-BC283F5F-E9CE-4095-AB01-A89A47945284Q37698252-08F95140-DD64-42B9-8890-4FE2791DA517Q37791483-EE389C56-12C6-44B1-A6DE-13860B8D3F28Q38011335-F0C303F6-70D8-4A49-9111-B006D93C3688Q38111306-24BA0FE4-1CC8-473E-81E1-EDC431CBDA70Q38233780-CD26BB89-6122-4F76-BB03-3197D67BA221Q38448022-6420206F-D43C-40A1-8E8F-9E85FA2C2AE2
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Scott B. Cantor
@ast
Scott B. Cantor
@en
Scott B. Cantor
@es
Scott B. Cantor
@nl
Scott B. Cantor
@sl
type
label
Scott B. Cantor
@ast
Scott B. Cantor
@en
Scott B. Cantor
@es
Scott B. Cantor
@nl
Scott B. Cantor
@sl
altLabel
Scott B. Cantor
@en
prefLabel
Scott B. Cantor
@ast
Scott B. Cantor
@en
Scott B. Cantor
@es
Scott B. Cantor
@nl
Scott B. Cantor
@sl
P106
P1153
7006009273
P21
P2456
P31
P496
0000-0002-7072-6048